MarketCap
Facebook
X
TelegramQuarterly report 2023-Q3
added 11-09-2023
Aravive Retained Earnings 2011-2026 | ARAV
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings Aravive
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -616 M | -540 M | -501 M | -470 M | -451 M | -374 M | -289 M | -193 M | -111 M | -55.3 M | -35.2 M | -22 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -22 M | -616 M | -305 M |
Quarterly Retained Earnings Aravive
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -627 M | -648 M | -666 M | -616 M | -587 M | -571 M | -553 M | -540 M | -527 M | -516 M | -509 M | -501 M | -501 M | -501 M | -501 M | -470 M | -470 M | -470 M | -470 M | -451 M | -451 M | -451 M | -451 M | -374 M | -374 M | -374 M | -374 M | -289 M | -289 M | -289 M | -289 M | -193 M | -193 M | -193 M | -193 M | -111 M | -111 M | -111 M | -111 M | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -111 M | -666 M | -408 M |
Retained Earnings of other stocks in the Biotechnology industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
-198 M | - | 5743.5 % | $ 69.7 M |  Canada |
 |
MorphoSys AG
MOR
|
-158 M | - | 2.43 % | $ 254 M |  Germany |
 |
Happiness Biotech Group Limited
HAPP
|
-70.3 M | - | 1.35 % | $ 17.8 M |  China |
 |
Amphastar Pharmaceuticals
AMPH
|
667 M | $ 16.88 | -2.43 % | $ 789 M |  USA |
 |
AgeX Therapeutics
AGE
|
-63.5 M | - | -10.17 % | $ 12.2 K | USA |
 |
Compugen Ltd.
CGEN
|
-453 M | $ 2.79 | -8.09 % | $ 261 M |  Israel |
 |
Coherus BioSciences
CHRS
|
-1.38 B | $ 1.6 | -2.15 % | $ 187 M | USA |
 |
I-Mab
IMAB
|
-8.33 B | - | - | $ 866 M | China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.24 B | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
-17.1 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
-405 M | - | 2.54 % | $ 160 B | France |
 |
AstraZeneca PLC
AZN
|
11 B | - | - | $ 96.9 B |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-108 M | - | -1.52 % | $ 24.7 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
-515 M | $ 7.56 | -3.45 % | $ 207 M | Israel |
 |
Athira Pharma
ATHA
|
-512 M | - | - | $ 269 M | USA |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
-325 M | - | 0.74 % | $ 768 M | Israel |
 |
Galera Therapeutics
GRTX
|
-307 M | - | -32.59 % | $ 7.61 M | USA |
 |
Esperion Therapeutics
ESPR
|
-1.62 B | $ 3.13 | 0.32 % | $ 651 M | USA |
 |
Exelixis
EXEL
|
-76.8 M | $ 50.41 | -1.36 % | $ 13.7 B | USA |
 |
Fortress Biotech
FBIO
|
-734 M | $ 2.43 | 5.65 % | $ 67.8 M | USA |
 |
Midatech Pharma plc
MTP
|
-156 M | - | -18.52 % | $ 27.3 M | Britain |
|
Forte Biosciences
FBRX
|
-223 M | $ 23.1 | -3.57 % | $ 299 M | USA |
 |
Fennec Pharmaceuticals
FENC
|
-229 M | $ 9.76 | 5.63 % | $ 279 M | USA |
 |
AbCellera Biologics
ABCL
|
-29.5 M | $ 4.09 | -7.05 % | $ 1.22 B | Canada |
 |
Autolus Therapeutics plc
AUTL
|
-1.39 B | $ 1.59 | - | $ 423 M | Britain |
 |
Институт стволовых клеток человека
ISKJ
|
69.4 M | - | - | - |  Russia |
 |
BioNTech SE
BNTX
|
18 B | $ 89.16 | -3.08 % | $ 21.5 B | Germany |
 |
Checkmate Pharmaceuticals
CMPI
|
-201 M | - | - | $ 231 M | USA |
 |
Galectin Therapeutics
GALT
|
-433 M | $ 2.22 | -5.74 % | $ 142 M | USA |
 |
Gilead Sciences
GILD
|
13.7 B | $ 130.07 | -1.51 % | $ 162 B | USA |
 |
Genmab A/S
GMAB
|
7.11 B | $ 26.8 | -0.37 % | $ 1.73 B |  Danmark |
 |
Advaxis
ADXS
|
-197 M | - | -9.65 % | $ 45.9 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-176 M | $ 3.41 | -2.25 % | $ 5.61 M | Israel |
 |
Aeterna Zentaris
AEZS
|
-20.5 M | - | 5.93 % | $ 314 M | Canada |
 |
Aeglea BioTherapeutics
AGLE
|
-1.13 B | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
-1.06 B | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
-308 M | - | - | $ 26.5 M | USA |
 |
Grifols, S.A.
GRFS
|
619 M | $ 7.74 | -0.64 % | $ 5.26 B |  Spain |
 |
AIkido Pharma
AIKI
|
-268 M | - | 1.93 % | $ 17.4 M | USA |
|
Enlivex Therapeutics Ltd.
ENLV
|
1.11 B | $ 0.72 | -1.05 % | $ 32.9 M | Israel |
 |
Akero Therapeutics
AKRO
|
-826 M | - | - | $ 3.67 B | USA |
 |
Eton Pharmaceuticals
ETON
|
-112 M | $ 29.69 | -0.92 % | $ 799 M | USA |
 |
Aptose Biosciences
APTO
|
-566 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
-353 M | - | -39.0 % | $ 4.57 M | USA |
 |
Akouos
AKUS
|
-168 M | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
-301 M | - | -0.23 % | $ 916 M | USA |
 |
AlloVir
ALVR
|
-160 M | - | 4.14 % | $ 49.1 M | USA |
 |
Allakos
ALLK
|
-1.12 B | - | - | $ 28.6 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-1.14 B | $ 21.51 | -0.3 % | $ 2.74 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
-246 M | - | 3.16 % | $ 1.9 M | USA |